Ph 3 Trial of BNT323/DB-1303 Met Primary Endpoint of PFS in HER2+ve Metastatic or Unresectable Breast Cancer September 10, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
Jaypirca significantly improved PFS in patients with treatment-naïve CLL/SLL in the Ph 3 BRUIN CLL-313 study September 9, 2025
Epcoritamab Demonstrates High Response Rates, Safe Outpatient Use in Ph 2 EPCORE® NHL-6 Study in DLBCL September 9, 2025
Survival benefit for bemarituzumab + chemo in 1L gastric cancer attenuates at final analysis September 9, 2025
Robust 24-month CR rate of 41.8% observed for cretostimogene monotherapy in BCG-unresponsive high-risk NMIBC patients September 9, 2025
Positive Data From Ph 1/2 Combo Trial of IDE397 and Trodelvy® in MTAP-Deletion Urothelial Cancer Announced September 9, 2025
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current SOC September 9, 2025
Positive Interim Ph 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma Announced September 9, 2025
WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets September 9, 2025
WCLC 2025: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in 1L EGFRm NSCLC September 9, 2025
WCLC 2025: Longer-Term Follow-Up of Patients Showed Improving, Favorable Trend in OS in Ph 3 HARMONi Clinical Trial for Ivonescimab + Chemo in 2L+ EGFRm NSCLC September 9, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
WCLC 2025: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with ES SCLC in IDeate-Lung01 Ph 2 Trial September 9, 2025
WCLC 2025: New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive NSCLC Announced September 9, 2025
Positive Topline Results for Sonrotoclax in R/R MCL Announced; primary endpoint of ORR met September 3, 2025
Initial Data Shows 100% Disease Control in all 5 Recurrent GBM patients and Near CR in 2, Treated With ANKTIVA® + Optune Gio® Device September 3, 2025
Ongoing Ph 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma showed 66% ORR and 50% CR in NHL patients September 3, 2025
Verzenio® (abemaciclib) increases OS in HR+, HER2-, high-risk early breast cancer with two years of therapy September 3, 2025
Nature Medicine Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Plus Tagitanlimab in 1L NSCLC August 26, 2025
Final Topline Survival Data from VERSATILE-002 Ph 2 Trial in 1L R/M HNSCC showing median OS of 39.3 months in patients with CPS ≥ 1 announced August 26, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
PADCEV Plus KEYTRUDA Significantly Improves Survival for Cisplatin-ineligible MIBC Patients When Given Before and After Surgery August 19, 2025
